Department of Radiation Oncology, E-Da Hospital, Kaohsiung, Taiwan; College of Medicine, I-Shou University, Kaohsiung, Taiwan.
Department of Chest Surgery, China Medical University Hospital, Taichung, Taiwan.
Thorac Cancer. 2020 Jan;11(1):113-119. doi: 10.1111/1759-7714.13244. Epub 2019 Nov 19.
Image-guided radiotherapy (IGRT) is an advanced radiotherapy technique to improve the accuracy of treatment delivery. However, a recent randomized controlled trial (RCT) for prostate cancer patients treated with radiotherapy either via IGRT or routine care (no daily IGRT) reported a statistically significant worse overall survival for those treated with IGRT. This raised the concern regarding the effectiveness of IGRT for definitive concurrent chemoradiotherapy (dCCRT) for locally advanced esophageal squamous cell carcinoma (LA-ESqCC).
Eligible LA-ESqCC patients diagnosed between 2011 and 2015 were identified via the Taiwan Cancer Registry. We estimated propensity scores to construct a 1:1 propensity-score-matched groups and balance observable potential confounders. The hazard ratio (HR) of death as well as other outcomes was compared between IGRT and non-IGRT matched groups during the entire follow-up period. The impact of additional covariables was considered in the sensitivity analysis.
Our study population included 590 patients in the primary analysis. The HR for death when IGRT was compared with non-IGRT was 0.92 (95% confidence interval 0.77-1.10, P = 0.35). There were also no significant differences for other outcomes or sensitivity analyses.
In this updated nonrandomized study using real world data, we found that the overall survival of LA-ESqCC patients treated with dCCRT was not statistically different between those treated with IGRT versus those without IGRT, although the hazard ratio was less than unity, ie, in favor of IGRT. The results should be interpreted with caution given the nonrandomized design and RCTs are needed to clarify our findings.
Significant findings of the study: The OS of LA-ESqCC patients treated with dCCRT was not statistically different between those treated with IGRT versus those without IGRT, although the hazard ratio was less than unity, ie, in favor of IGRT.
In this updated nonrandomized study using real world data with additional potential confounders, our study provided a reasonable tentative evidence of lack of RCT as suggested in the literature.
图像引导放疗(IGRT)是一种提高治疗准确性的先进放疗技术。然而,最近一项针对接受放疗的前列腺癌患者的随机对照试验(RCT)报告称,接受 IGRT 治疗的患者总体生存率明显较差,而接受常规治疗(无每日 IGRT)的患者则无此情况。这引发了人们对 IGRT 在局部晚期食管鳞状细胞癌(LA-ESqCC)根治性同步放化疗(dCCRT)中的有效性的关注。
通过台湾癌症登记处,确定了 2011 年至 2015 年间诊断为 LA-ESqCC 的合格患者。我们估计倾向评分来构建 1:1 倾向评分匹配组,并平衡可观察到的潜在混杂因素。在整个随访期间,比较 IGRT 组和非 IGRT 匹配组的死亡风险比(HR)以及其他结局。在敏感性分析中考虑了额外协变量的影响。
我们的研究人群包括主要分析中的 590 名患者。IGRT 组与非 IGRT 组相比,死亡的 HR 为 0.92(95%置信区间 0.77-1.10,P=0.35)。其他结局或敏感性分析也没有显著差异。
在这项使用真实世界数据的非随机更新研究中,我们发现,接受 dCCRT 治疗的 LA-ESqCC 患者的总体生存率在接受 IGRT 治疗与未接受 IGRT 治疗的患者之间没有统计学差异,尽管 HR 小于 1,即有利于 IGRT。鉴于非随机设计,结果应谨慎解释,需要 RCT 来澄清我们的发现。
接受 dCCRT 治疗的 LA-ESqCC 患者的 OS 在接受 IGRT 治疗与未接受 IGRT 治疗的患者之间无统计学差异,尽管 HR 小于 1,即有利于 IGRT。
在这项使用真实世界数据的更新非随机研究中,我们加入了额外的潜在混杂因素,为缺乏 RCT 提供了合理的初步证据,这与文献中的建议一致。